Chagas Disease Epidemiology and Treatment Strategies

Chagas disease, caused by the protozoan Trypanosoma cruzi, remains a major public health challenge in Latin America and an emerging concern worldwide. Transmission occurs primarily through infected triatomine vectors, but blood transfusion, organ transplantation and congenital routes also contribute substantially to new cases. After an acute phase that may be mild or asymptomatic, many patients progress to a chronic stage characterised by cardiac and gastrointestinal complications decades after infection. Epidemiological surveillance has documented both a decline in vectorial transmission in some endemic regions and a concurrent rise in diagnoses outside Latin America due to migration. Control strategies combine insect‐vector management, blood‐donor screening and maternal screening programmes. Treatment relies on antiparasitic drugs, notably benznidazole, which is most effective in acute and early chronic infections but offers variable benefit in longstanding disease. Advances in diagnostic and monitoring tools, together with refined understanding of parasite diversity and host immune responses, are guiding novel interventions and informing global efforts to reduce the burden of Chagas disease.

Research from Nature Portfolio

Proteome‐wide mapping of T. cruzi antigens has delineated more than 230 linear epitopes recognised by patient antibodies, revealing core functional residues that underpin serological reactivity. High‐density peptide arrays applied to diverse patient cohorts across the Americas have identified a panel of antigens with strong diagnostic performance, even in challenging chronic infections. These data represent the most comprehensive antibody‐epitope atlas to date and offer a foundation for next‐generation serological assays and potential antigen‐based vaccine candidates.

Chagas Disease Epidemiology and Treatment Strategies publication trend

The graph below shows the total number of articles in chagas disease epidemiology and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Trypanosoma cruzi: The protozoan parasite that causes Chagas disease.

Vectorial transmission: Infection spread via blood‐feeding insects (triatomine bugs).

Serological biomarker: A blood‐based indicator used to detect immune response to T. cruzi.

Congenital transmission: Mother‐to‐child passage of the parasite during pregnancy or birth.

Benznidazole: A frontline antiparasitic drug indicated for acute and early chronic Chagas disease.

References

1. The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas. Nature Communications (2023).
2. Chagas Disease: From Discovery to a Worldwide Health Problem. Frontiers in Public Health (2019).
3. Estimating the Burden of Chagas Disease in the United States. PLOS Neglected Tropical Diseases (2016).
4. Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas. PLOS Neglected Tropical Diseases (2014).